DSGNDesign Therapeutics, Inc.
14.99USD-5.96%Mkt Cap: 938.10M $P/E: —3d ago
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The compa…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap938.10M $
Enterprise Value769.04M $
Revenue (TTM)—
Gross Profit-58.78M $
Net Income (TTM)-69.79M $
Revenue/Share—
Last Price14.99 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees55
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-9.77
PEG—
EV/EBITDA-9.82
EV/Revenue—
P/S—
P/B4.82
EPS (TTM)-1.15
EPS (Forward)-1.59
52W Range
4.68082% of range17.25
52W High17.25 USD
52W Low4.680 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-32.84%
ROA-30.85%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-54.36M $
CapEx (TTM)193.00K $
FCF Margin—
FCF Yield-3.45%
Net Debt-204.73M $
Net Debt/EBITDA2.61
Balance Sheet
Debt/Equity0.01
Current Ratio18.86
Quick Ratio18.61
Book Value/Sh3.226 USD
Cash/Share3.314 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)21.00 USD
Upside (mean)+40.1%
Target Range20.00 USD – 22.00 USD
$20.00+40.1% to mean$22.00
# Analysts6
Ownership
Shares Out.62.58M
Float36.19M
Insiders31.87%
Institutions78.58%
Short Interest
Short Ratio8.4d
Short % Float12.60%
Short % Out.9.51%
Shares Short5.95M
Short (prev mo.)5.72M
Technical
SMA 5013.38 (+12.1%)
SMA 20011.19 (+33.9%)
Beta1.64
S&P 52W Chg18.16%
Avg Vol (30d)483.57K
Avg Vol (10d)503.48K
Technical Indicators
RSI (14)61.2
MACD0.6426
MACD Signal0.4238
MACD Hist.+0.2188
BB Upper16.18 USD
BB Middle13.51 USD
BB Lower10.83 USD
BB Width39.61%
ATR (14)0.7838 USD
Vol Ratio (20d)1.27x